Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI learns to spot bladder cancer under blue light

NCT ID NCT07144319

Diagnosis Sponsor: Photocure Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 4 times

Summary

This study collects video recordings and data from 500 patients undergoing blue light cystoscopy, a procedure where a drug makes cancer cells glow. The goal is to train an artificial intelligence (AI) algorithm to detect bladder lesions in real time, helping doctors make more accurate decisions during routine exams. No new treatments are being tested—only data is being gathered to develop the AI tool.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hexvix/Cysview (a drug that makes cancer cells glow under blue light)
What this could lead to
If successful, this could lead to an AI tool that helps doctors spot bladder cancer more reliably during cystoscopy, potentially reducing missed lesions.
What could go wrong
This is an early data-collection study, not a treatment trial. The AI is not yet tested in real-time use, and results may not translate into immediate patient benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Routine clinical practice patients scheduled for BLC

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 or older * Written informed consent, approved by relevant IRB/IEC, signed * Hexvix/Cysview has been prescribed in the usual manner in accordance with the terms of the marketing authorization (see Appendix B) * Physician has planned to do a blue light cystoscopy on the patient and to obtain biopsies, if clinically indicated, of suspicious lesions with video confirmation. * Patient has not previously taken part in this study Exclusion Criteria: * None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bladder cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms superficial urinary bladder carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bladder cancer Non-muscle invasive bladder cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    8 sites in 5 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Department of Urology, University Medical Center Hamburg-Eppendorf (UKE)

    RECRUITING

    Hamburg, Germany

  • Marien Hospital Herne, Universitätsklinikum der Ruhr-Universität Bochum

    NOT_YET_RECRUITING

    Herne, Germany

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

  • Oslo University Hospital

    RECRUITING

    Oslo, Norway

  • Regents of the University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48108, United States

  • Rutgers Cancer Institute

    RECRUITING

    New Brunswick, New Jersey, 08901, United States

  • UZ Leuven

    RECRUITING

    Leuven, Belgium

  • Vancouver Prostate Centre at Vancouver General Hospital

    RECRUITING

    Vancouver, Canada

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.